Text Size

Biodegradable intraocular therapies for retinal disorders: Progress to date

Kuno N., Fujii S.


  • 2010
  • Drugs and Aging
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Drug Delivery

  • Affiliations

    Research and Development Center, Santen Pharmaceutical Co. Ltd, 8916-16, Takayama-cho, Ikoma-shi, Nara 630-0101, Japan

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.


Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022